prostate cancer
Conditions
Interventions
observation group:Included patients in the treatment with revalutamide
Sponsors
Cancer Hospital Affiliated to Xinjiang Medical University
Eligibility
Sex/Gender
Male
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1) Age= 18 years old 2) Patients diagnosed with metastatic hormone-sensitive prostate cancer 3) Investigator assessment that revilutamide can be used, or has received or is receiving revilutamide therapy; 4) Signed informed consent and voluntarily joined this study 5) Male patients whose partner is a female of childbearing potential should be surgically sterile or agree to use an effective method of contraception during the trial and for 3 months after the last administration of study drug.
Exclusion criteria
Exclusion criteria: 1: Participating in other drug intervention clinical studies; 2: Other conditions judged by the investigator to be inappropriate for inclusion in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| safety analysis; | — |
Secondary
| Measure | Time frame |
|---|---|
| Duration of medication;Time to start the first follow-up anti-prostate cancer therapy;rPFS(Investigator evaluation);MFS;OS;Objective response rate of soft tissue lesions;SSE;Until the pain progresses;pharmacoeconomics;PSA; | — |
Countries
China
Contacts
Public ContactBiXing
Cancer Hospital Affiliated to Xinjiang Medical University
Outcome results
None listed